Sequana Medical NV represents values of innovation, patient-centricity, and continuous improvement. The company is driven by a corporate philosophy focused on delivering transformative medical solutions that enhance the lives of patients with managing fluid overload conditions. With a dedicated team and cutting-edge technology, Sequana Medical NV aims to provide effective therapy options and improve the clinical outcomes of patients. Through its commitment to advancing medical knowledge and providing exceptional care, Sequana Medical NV demonstrates a strong sense of responsibility towards enhancing the well-being of people dealing with fluid-related disorders.

Sequana Medical NV is primarily present in various countries and regions. The company's global presence extends to multiple regions, including Europe, North America, and Asia. Their expanding reach allows them to serve a diverse range of markets and customers. Sequana Medical NV's commitment to international growth enables them to deliver their innovative medical solutions and advanced technologies to patients and healthcare providers worldwide. By prioritizing global expansion, Sequana Medical NV positions itself as a leading player in the global healthcare industry, focusing on improving patient outcomes and enhancing the quality of care across different geographical locations.

Sequana Medical NV has achieved several significant milestones. First, the company successfully developed and gained regulatory approvals for its innovative alfapump system, a unique solution for fluid overload in patients with liver disease and malignant ascites. Additionally, Sequana Medical NV secured CE Mark approval for alfapump for the treatment of refractory ascites, addressing a significant unmet medical need. The company also expanded its market presence by launching the alfapump system commercially across select European countries. Overall, Sequana Medical NV's achievements demonstrate its commitment to advancing medical solutions and improving patient outcomes in the field of liver disease and fluid management.

Sequana Medical NV is a Belgium-based medical device company that focuses on developing innovative solutions for the management of fluid overload in patients suffering from liver disease, heart failure, and other conditions. Founded in 2006, Sequana Medical has a strong background in medical technology and a rich history in conducting extensive research and clinical trials. The company has successfully developed the Alfapump System, a fully implantable wireless device that provides automated and personalized treatment for fluid management. Sequana Medical NV aims to revolutionize the treatment approach for patients with fluid overload, offering improved quality of life and reduced healthcare costs.

The main competitors of Sequana Medical NV in the market include companies such as Medtronic, Abbott Laboratories, and Boston Scientific Corporation. These notable players in the medical devices industry offer similar products and solutions, making competition fierce within the market. Sequana Medical NV strives to maintain its competitive edge through its innovative technologies and unique offerings.

Sequana Medical NV is primarily active in the medical industry.

The business model of Sequana Medical NV revolves around the development and commercialization of innovative medical devices. The company focuses on addressing unmet clinical needs in the management of fluid overload conditions. Sequana Medical's flagship product, the alfapump®, is a fully implantable system designed to manage fluid within the body. By offering a personalized and automatic solution for patients with conditions like liver disease, heart failure, and cancer, Sequana Medical aims to improve patient outcomes and enhance their quality of life. Through continuous innovation and strategic partnerships, Sequana Medical NV aims to be a leading provider of transformative solutions in the field of fluid management.

Det Sequana Medical P/E-forhold er -0,78.

Sequana Medical KUV er 79,89.

AlleAktien Kvalitetsscore for Sequana Medical er 4/10.

Den forventede Sequana Medical omsætning er 309.000,00 EUR.

Den forventede Sequana Medical indtjening er -31,50 mio. EUR.

Sequana Medical NV is a medical technology company specializing in the development of innovative medical devices for the treatment of chronic fluid accumulations in the body. The company was founded in Belgium in 2006 and is headquartered in Ghent. The business model of Sequana Medical NV includes three main segments: the development and marketing of medical devices, the manufacturing of medical products, and distribution partners. The core product of Sequana Medical NV is the alfapump System, an implantable medical device that helps regulate the movement of fluids in the body and thereby alleviate symptoms of chronic edema and ascites. The alfapump System is a closed system that pumps fluid out of the body while simultaneously introducing new fluid to maintain fluid balance in the body. The second main segment of Sequana Medical NV is the manufacturing of medical products used to support the alfapump. These include hoses, needles, and connectors, for example. The third segment of Sequana Medical NV is the distribution of medical devices. The company has distribution partners in Europe, Asia, and the USA who sell and distribute the alfapump System and other products from Sequana Medical NV. Sequana Medical NV is committed to expanding its business in the international market. The company works closely with doctors and healthcare professionals to improve the effectiveness of its products and ensure that patients worldwide can benefit from them. To further accelerate the growth of Sequana Medical NV, the company recently conducted a capital increase. The proceeds from the capital increase will be used to finance further research and development and to expand the product offering of Sequana Medical NV. Overall, the business model of Sequana Medical NV is focused on developing, manufacturing, and distributing innovative medical devices for the treatment of fluid accumulations in the body. With the alfapump System and other products, the company has already established a significant presence in the global market and actively works to improve its offerings to meet the needs of patients worldwide.

Sequana Medical udbetaler et udbytte på 0 EUR fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Sequana Medical, eller selskabet udbetaler ikke udbytte.

ISIN'en for Sequana Medical er BE0974340722.

WKN for Sequana Medical er A2PD78.

Tickeren for Sequana Medical er SEQUA.BR.

I løbet af de sidste 12 måneder betalte Sequana Medical en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Sequana Medical sandsynligvis betale en dividende på 0 EUR.

Udbytteafkastet for Sequana Medical er i øjeblikket .

Sequana Medical betaler kvartalsvis udbytte. Dette uddeles i månederne .

Sequana Medical betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 EUR. Dette svarer til et dividendeafkast på 0 %.

Sequana Medical bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Sequana Medical fra den 21.9.2024 på 0 EUR, skulle du have haft aktien i din portefølje før ex-datoen den 21.9.2024.

Udbetalingen af det sidste udbytte blev foretaget den 21.9.2024.

I løbet af 2023 udbetalte Sequana Medical 0 EUR i form af dividender.

Udbytterne fra Sequana Medical udbetales i EUR.